Vicore Pharma Holding AB
NASDAQ:VCRE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vicore Pharma Holding AB
NASDAQ:VCRE
|
SE |
|
Pieris Pharmaceuticals Inc
F:PI6
|
US |
|
P
|
Perion Network Ltd
F:IW2
|
IL |
|
Microstrategy Inc
BMV:MSTR
|
US |
|
Windar Photonics PLC
F:7WP
|
DK |
|
P
|
Polytec Holding AG
VSE:PYT
|
AT |
|
V
|
Vallourec SA
F:VACD
|
FR |
|
Mizuno Corp
TSE:8022
|
JP |
|
Astellas Pharma Inc
F:YPHA
|
JP |
|
M
|
Memphasys Ltd
ASX:MEM
|
AU |
|
H
|
HB Investment Inc
KOSDAQ:440290
|
KR |
|
Isuzu Motors Ltd
F:ISU
|
JP |
|
China Conch Venture Holdings Ltd
F:68C
|
CN |
|
K
|
Koses Co Ltd
KOSDAQ:089890
|
KR |
Intrinsic Value
Is VCRE undervalued or overvalued?
See the intrinsic value estimate for 
Vicore Pharma Holding AB and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Vicore Pharma Holding AB Does
Vicore Pharma Holding AB is a Swedish drug developer focused on serious lung diseases and scarring disorders, especially idiopathic pulmonary fibrosis. It does not sell consumer products; instead, it develops prescription medicines, runs clinical studies, and works to turn its drug candidates into approved treatments. Its main scientific idea is to target the body’s angiotensin II type 2 receptor, which it believes may help slow or reduce fibrosis.
- Headquarters
- Sweden SE
- Employees
- 37
- IPO date
- Dec 10, 2015
Revenue & Expenses Breakdown
Vicore Pharma Holding AB
Earnings Waterfall
Vicore Pharma Holding AB
The intrinsic value for Vicore Pharma Holding AB (VCRE) under the Base Case is hidden USD.
Compared with the current market price of 9.16 USD, the stock appears hidden.
